IL10 and neoplasm: Analysis of the pharmacodynamic (PD) cytokine response 3 days after dosing (Figure 4B) showed that mIL12-FHAB-hIL15 increased IFNγ, IL-10, IL-12, IL-6, and TNFα levels in a dose-dependent manner compared to the tumor-bearing placebo group, with no evidence of cytokine release syndrome.